Drug Patents owned by Sanofi Aventis Us
1. Drug name - AUBAGIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(3 years from now) | |
|
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(4 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) | |
|
US8802735
(Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(8 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(11 years from now) | |
|
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) | |
Drugs and Companies using TERIFLUNOMIDE ingredient
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 7MG | TABLET;ORAL | Prescription |
| 14MG | TABLET;ORAL | Prescription |
2. Drug name - JEVTANA KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(3 years from now) | |
| CN1849311A | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| CN100429207C | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| IN200600944P4 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| IN253669B | SANOFI AVENTIS US | A Process For The Preparation Of Acetone Solvate Of Dimethoxy Docetaxel |
Sep, 2024
(1 year, 11 months from now) | |
| EP1667986B1 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Mar, 2026
(3 years from now) | |
| EP1667986A1 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7241907
(Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(3 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
|
US8927592
(Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(8 years from now) | |
Drugs and Companies using CABAZITAXEL ingredient
Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 60MG/1.5ML (40MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
3. Drug name - MULTAQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(6 years from now) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(6 years from now) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(8 years from now) | |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 400MG BASE | TABLET;ORAL | Prescription |
4. Drug name - OFORTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148207 | SANOFI AVENTIS US | Oral fludara of high-purity formulation with quick release of active ingredient |
Dec, 2022
(2 months from now) | |
Drugs and Companies using FLUDARABINE PHOSPHATE ingredient
Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.